[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100484953":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":7,"responsibleParty":23,"collaborators":25,"id":29,"slug":7,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":7,"eligibilityCriteria":34,"healthyVolunteers":30,"sex":35,"minAge":36,"maxAge":37,"enrollmentInfo":7,"targetDuration":7,"studyType":38,"phases":7,"briefSummary":39,"conditions":7,"keywords":40,"overallStatus":42,"whyStopped":7,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":47,"locationsCount":7},{"fullName":5,"class":6},"Ascentage Pharma Group Inc.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Olverembatinib","Oral Olverembatinib",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Tanner Pharma","CONTACT","704-552-8408","olverembatinib@tannerpharma.com",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"NPP Core working Group","301-291-5658","NPP-olverembatinib@ascentage.com",{"type":24,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[26],{"name":27,"class":28},"Tanner Pharma Group","OTHER","100484953",false,"NCT05594758","Named Patient Program for Olverembatinib (HQP1351)","Named Patient Program for Providing Access to Olverembatinib (HQP1351) to Countries Where the Drug is Not Available","Inclusion Criteria:\n\n• Patients who are suitable to receive Olverembatinib and for whom there is reasonable expectation that Olverembatinib may provide clinical benefit based on the medical judgment of their prescribing physician.\n\nExclusion Criteria:\n\n* Existing risks of serious Arterial occlusive events (AOE), including myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and recent revascularization procedures\n* Existing risks of serious Venous thromboembolic events (VTEs), including deep venous thrombosis, pulmonary embolism, and retinal vein thrombosis\n* Existing serious heart conditions, including acute\u002Fchronic heart failure, coronary artery disease\n* Existing conditions of severe liver malfunction\n* Existing conditions of severe myelosuppression\n* Existing conditions of severe hemorrhage\n* Pregnant or baby feeding","ALL","18 Years","99 Years","EXPANDED_ACCESS","This program will allow eligible patients access to Ascentage Pharma's novel drug candidate Olverembatinib (approved in China) on a named patient basis in over 100 countries ( with the exception of the USA and China) and regions where the drug is not available.",[41],"Named Patient Program","AVAILABLE","2024-02-06",{"date":45,"type":46},"2024-02-07","ACTUAL",{"name":5,"class":6}]